JAMA Dermatology是美国医学会(AMA)旗下专注于皮肤病学领域的国际顶级学术期刊，致力于发表皮 肤疾病机制、创新疗法及临床实践的前沿研究。(CIS) 这是一项多中心、随机、双盲、安慰剂对照的II期临床研究，旨在评估Soficitinib治疗中重度特应性皮炎 患者的安全性和有效性。75名患者随机分成三组：Soficitinib80毫克每天一次(QD)组、Soficitinib120毫 克QD组和安慰剂组。主要终点为安全性和有效性。关键疗效终点为第4周时湿疹面积和严重程度指数 (EASI)较基线的百分比变化，其他终点包括达到第4周EASI-75(EASI较基线改善≥75%)的患者比例，以 及第四周经验证的研究者整体评估(vIGA)达到皮损完全清除(0分)或皮损基本清除(1分)且评分改善≥2分 的患者比例。 研究表明，Soficitinib达到了多个疗效终点。Soficitinib可以强效快速改善皮损，治疗第四周80毫克QD和 120毫克QD两个治疗组EASI评分较基线改善的百分比分别为78.2%和72.5%，而安慰剂组为16.7%；治疗 第四周两个治疗组EASI-75应答率均为64.0%，较安慰剂组 ...

Envudeucitinib的临床疗效，综合两项试验的数据显示： Alumis 1月6日宣布，其 下一代口服TYK2抑制剂Envudeucitinib （ESK-001）在两项针对中度至重度 斑块状银屑病 的关键性 三期临床试验 （ONWARD1和ONWARD2）中 取得了积极的顶线结果 。数据 表明，该药物在 皮肤清除率方面表现出 Best-in-class 的潜力 ，所有主要终点和次要终点均以极高的统 计学显著性达成。受此消息影响，周二 Alumis股价大涨95.31%，市值近17亿美元。 从机制上看，envudeucitinib作为一种新一代的高选择性口服TYK2抑制剂，能够最大限度地抑制 TYK2，从而阻断IL-23和IL-17这两条关键通路，实现对疾病的全面控制。Alumis首席医疗官 Jörn Drappa博士指出，这种机制转化为了临床上快速的起效时间和高比率的皮肤清除率，其症状 改善程度在口服疗法中名列前茅。在安全性方面，该药物在两项试验中均表现出良好的耐受性， 安全性特征与此前的II期项目一致，未发现新的安全信号。治疗期间出现的不良事件大多为轻度 至中度，最常见的包括头痛、鼻咽炎、上呼吸道感染 ...

Core Viewpoint - Eli Lilly is in late-stage negotiations to acquire biotech company Ventyx Biosciences for over $1 billion, leading to a 57% surge in Ventyx's stock price after market close [1]. Company Overview - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune diseases, inflammatory diseases, and neurodegenerative diseases [2]. - The company's core pipeline includes NLRP3 inhibitors, with key products VTX2735 and VTX3232, both in Phase 2 development [2][3]. Product Pipeline and Clinical Development - VTX2735 is a peripheral NLRP3 inhibitor targeting recurrent pericarditis, with Phase 2 data expected in the second half of 2025 [3][4]. - VTX3232 is a CNS-penetrant NLRP3 inhibitor aimed at treating Parkinson's disease and cardiometabolic diseases, with positive Phase 2a data anticipated in June 2025 and additional data expected in the second half of 2025 [3][4]. - The inflammatory bowel disease portfolio includes Tamuzimod, a Phase 3-ready S1P1R modulator for ulcerative colitis, and VTX958, a TYK2 inhibitor for Crohn's disease, which has completed Phase 2 trials [3][4]. Financial Position - As of March 31, 2025, Ventyx reported cash, cash equivalents, and marketable securities totaling $228.8 million, expected to fund operations into at least the second half of 2026 [3].

Group 1 - The company, Innovent Biologics, announced significant progress in clinical research for its novel TYK2 inhibitor soficitinib, with the completion of patient enrollment for a Phase III registration clinical trial for moderate to severe atopic dermatitis (AD) [1] - The Phase III trial for AD included 579 patients, while the Phase II trial for vitiligo enrolled 162 patients, both trials being randomized, double-blind, and placebo-controlled [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed by the company, targeting various T-cell related autoimmune diseases, with a focus on dermatological conditions such as atopic dermatitis and vitiligo [1] Group 2 - According to WHO, there are approximately 230 million people globally suffering from atopic dermatitis, making it the most burdensome non-fatal skin disease, with nearly 70 million patients in China [2] - The Phase II clinical study of soficitinib for moderate to severe atopic dermatitis achieved multiple efficacy endpoints, demonstrating superior efficacy and safety compared to other treatment modalities [2] - Vitiligo affects around 70 million people globally, characterized by the destruction of skin melanocytes, requiring long-term treatment to control lesion progression and promote repigmentation [2] Group 3 - The CEO of Innovent Biologics emphasized the significant unmet clinical needs for both atopic dermatitis and vitiligo, expressing optimism about the progress of soficitinib in addressing these chronic diseases [2]

Core Viewpoint - InnoCare Pharma has received approval for a phase II clinical trial of its TYK2 inhibitor ICP-488 for treating cutaneous lupus erythematosus, marking a significant step in addressing unmet medical needs in autoimmune diseases [1][4]. Company Overview - InnoCare Pharma is a biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with operations in China and the United States [5]. Product Details - ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor that blocks the signal transduction of inflammatory cytokines, potentially offering a new treatment option for autoimmune diseases [2]. - The drug has shown favorable efficacy and safety in a phase II clinical trial for psoriasis, with plans for a phase III study nearing completion [4]. Disease Context - Cutaneous lupus erythematosus (CLE) is a common autoimmune disease characterized by skin lesions, which can progress to systemic lupus erythematosus affecting multiple organs [3].

Core Viewpoint - Nocera Biopharma (09969) has received approval from the National Medical Products Administration (NMPA) to conduct Phase II/III clinical trials for its novel TYK2 inhibitor soficitinib (ICP-332) aimed at treating chronic spontaneous urticaria (CSU) [1] Company Summary - Nocera Biopharma's stock rose by 3.87% to HKD 13.69, with a trading volume of HKD 37.91 million [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed for various T-cell related autoimmune diseases, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - The mechanism of soficitinib involves blocking cytokine signaling pathways that activate mast cells and inflammatory responses, thereby alleviating symptoms of CSU [1] Industry Summary - There are approximately 50 million patients suffering from chronic spontaneous urticaria globally, with the CSU market expected to reach USD 3 billion by 2029 [2]

Group 1 - The core viewpoint of the article highlights that Nocera Biopharma (09969) has received approval from the National Medical Products Administration (NMPA) to conduct Phase II/III clinical trials for its novel TYK2 inhibitor soficitinib (ICP-332) aimed at treating Chronic Spontaneous Urticaria (CSU) [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed by the company, targeting various T-cell related autoimmune diseases, with a strong focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - The TYK2 enzyme plays a crucial role in the JAK-STAT signaling pathway, which is significant in the inflammatory disease mechanism, and soficitinib works by blocking cytokine signaling pathways that activate mast cells and inflammatory responses, thereby alleviating symptoms of CSU [1] Group 2 - There are approximately 50 million patients suffering from Chronic Spontaneous Urticaria globally, and the CSU market is projected to reach $3 billion by 2029 [2]

Core Viewpoint - InnoCare Pharma has received approval for a Phase II/III clinical trial of its novel TYK2 inhibitor, soficitinib, aimed at treating chronic spontaneous urticaria (CSU), addressing significant unmet medical needs in the dermatology market [1][6]. Group 1: Drug Development - Soficitinib is a selective TYK2 inhibitor being developed for various T-cell related autoimmune disorders, including CSU, atopic dermatitis, and vitiligo [2]. - The drug works by blocking signaling pathways such as IL-4, IL-13, and IL-31, which are involved in mast cell activation and inflammation, thereby reducing symptoms like itch and wheals in CSU patients [3]. Group 2: Market Potential - Chronic spontaneous urticaria affects approximately 50 million patients globally, with the CSU treatment market projected to reach $3 billion by 2029 [5]. - The disease typically lasts two to five years, with some cases extending beyond five years, indicating a substantial need for long-term treatment options [4]. Group 3: Company Overview - InnoCare Pharma is focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with a robust pipeline targeting ten major autoimmune diseases [6]. - The company operates in multiple locations, including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, emphasizing its commitment to addressing unmet medical needs both in China and globally [6].

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, Aorite, and others [1]. Core Views - The pharmaceutical sector experienced a 3.29% increase this week, outperforming the CSI 300 index by 4.37 percentage points. Sub-sectors such as pharmaceutical commerce, pharmacies, and innovative drugs performed well, while medical devices and consumables lagged [2][12]. - The report emphasizes the importance of market pricing power and the impact of liquidity and risk appetite on investment strategies, particularly in innovative drugs and related supply chains [2][12]. - The report highlights the upcoming patent expirations for small molecule drugs, which are expected to create significant demand for raw materials, with a projected sales impact of $390 billion from 2025 to 2030 [3][13]. Summary by Sections Industry Performance - The pharmaceutical sector's performance this week was characterized by a 3.29% increase, with notable performances in pharmaceutical commerce (+7.31%), pharmacies (+6.83%), and innovative drugs (+5.01%). In contrast, medical devices (0.16%) and new medical infrastructure (1.18%) showed weaker performance [17][29]. - The overall price-to-earnings (P/E) ratio for the pharmaceutical industry is reported at 30.84 times, with a premium of 25.08% compared to the overall A-share market excluding the financial sector [33]. Company Dynamics - Notable company announcements include: - Prologis Pharmaceuticals received a European certificate for its product, enhancing its international market prospects [18]. - Jianyou Co. announced FDA approval for its production site, expanding its manufacturing capabilities [19]. - Fuyuan Pharmaceuticals received a drug registration certificate from the National Medical Products Administration, allowing for the marketing of its product [20]. - The report suggests focusing on companies benefiting from domestic innovative drug support policies, such as Yangguang Nuohuo and Nuosige, as well as those with strong overseas business prospects [15][7]. Raw Materials - The report indicates that the raw materials sector is expected to see a significant increase in demand due to patent expirations, with a projected sales impact of $390 billion from 2025 to 2030. The production of raw materials in H1 2025 reached 1.935 million tons, reflecting an 8.2% year-on-year increase [3][13]. - Companies recommended for attention in the raw materials sector include Aorite, Prologis Pharmaceuticals, and Aoxiang Pharmaceuticals, focusing on innovation and strong performance [3][16].

InnoCare Collaboration - Zenas BioPharma has a collaboration agreement with InnoCare Pharma, a biopharmaceutical company with a market cap exceeding $4.5 billion USD, two marketed products, and over 10 candidates in clinical development[9] - InnoCare will receive global rights to Orelabrutinib and ZB022, and global rights to ZB021 excluding China and Southeast Asia, while retaining global rights to Orelabrutinib in oncology indications[11] - Zenas will receive $35 million USD in cash and 5 million shares of Zenas common stock upfront from InnoCare[11] - Zenas is eligible for up to an additional 2 million shares of Zenas stock and up to $240 million USD in development and regulatory milestone payments for Orelabrutinib, as well as commercial sales milestone payments and tiered royalties on net sales[11] Orelabrutinib (BTKi) Program - A Phase 3 PPMS registration-directed trial has been initiated in the U S for Orelabrutinib, with a Phase 3 SPMS registration-directed trial expected to initiate in Q1 2026[11] - Orelabrutinib treatment in a Phase 2 RRMS trial resulted in a significant reduction in new GdE+ T1 lesions, with a >90% reduction observed at the 80mg QD dose at week 12 (P=0 0018)[48] - The global MS market is expected to exceed $30 billion USD, with SPMS and PPMS representing >$12 billion USD[61] Pipeline Programs - IND clearance and enrollment of the first patient for ZB021, an oral IL-17AA/AF inhibitor, and ZB022, a brain penetrant TYK2 inhibitor, are expected in 2026[11] - The anti-IL-17 biologics market is currently a $10 billion USD global market with ~50% average annual growth since first approval[74] Obexelimab Program - Phase 3 INDIGO trial for IgG4-RD is fully enrolled with topline results expected around year-end 2025[83] - Phase 2 MoonStone trial for RMS is fully enrolled with (12-week) data expected early Q4 2025[83] - Phase 2 SunStone trial for SLE is enrolling with (24-week) data expected mid-2026[83] - Obexelimab represents a compelling $1 billion+ USD commercial revenue opportunity in the U S alone for IgG4-RD[120]